

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



Organizational Changes, Changes in Board Members' and Corporate Officers' Responsibilities, and Personnel Changes of ASKA Pharmaceutical

TOKYO, September 4, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) announced the following organizational changes, changes in board members' and corporate officers' responsibilities, and personnel changes at its subsidiary, ASKA Pharmaceutical Co., Ltd., effective October 1, 2026.

1. Organizational Changes

To achieve “ASKA VISION 2035,” announced on May 20, 2026, and the “Mid-Term Management Plan 2028,” the initial three-year action plan toward its realization, ASKA Pharmaceutical will transfer and reorganize its pharmaceutical business and administrative functions.

These changes will clarify the allocation of authority and responsibility, strengthen collaboration across divisions, enable agile decision-making, and reinforce the management foundation for sustainable growth.

- (1) The Pharma Business Initiative will be newly established at the same organizational level as the existing divisions. The Sales Division, the Endocrine Business Unit currently under the direct control of the President, and the Medical Affairs Department currently under the Business Development Division will be transferred under the Pharma Business Initiative.
- (2) The Business Strategy & Transactions Unit, currently under the direct control of the President, will be abolished.
- (3) The Corporate Planning Department under the Administrative Division will be abolished, and its corporate planning functions will be transferred. To strengthen the functions for formulating and executing corporate strategy, the Corporate Strategy Division will be newly established, with the Corporate Strategy Office and the Corporate Management Department under it.
- (4) The Legal Affairs Department will be newly established under the Administrative Division.

2. Changes in Board Members' and Corporate Officers' Responsibilities

Board Member

Yutaka Kaihori	[New Responsibilities] Member of the Board of Directors, Executive Corporate Officer, Pharma Business Initiative [Current Responsibilities] Member of the Board of Directors, Executive Corporate Officer, Sales Division Director
----------------	--

Corporate Officers

Kiyohiko Tamura	[New Responsibilities] Executive Corporate Officer, Administrative Division Director Concurrently, Legal Affairs Department Director [Current Responsibilities] Executive Corporate Officer, Administrative Division Director
Atsushi Ito	[New Responsibilities] Corporate Officer, Sales Division Director, Pharma Business Initiative [Current Responsibilities] Corporate Officer, Assistant Division Director, Sales Division
Hideaki Kobayashi	[New Responsibilities] Corporate Officer, Corporate Strategy Division Director [Current Responsibilities] Corporate Officer, Assistant Division Director, Administrative Division

3. Personnel Changes

Kazuko Tamada	[New Responsibilities] Corporate Strategy Office Director, Corporate Strategy Division [Current Responsibilities] Business Strategy & Transactions Unit Director
Manabu Ichikawa	[New Responsibilities] Corporate Management Department Director Corporate Strategy Division [Current Responsibilities] Corporate Planning Department Director, Administrative Division
Shinya Yamada	[New Responsibilities] General Affairs Department Director, Administrative Division [Current Responsibilities] Administrative Division Assistant to Corporate Planning Department Director (Seconded to ASKA Pharmaceutical Holdings Co., Ltd.)

Reference (As of October 1, 2026)

ASKA Pharmaceutical Co., Ltd.

Board Members

Takashi Yamaguchi	Member of the Board of Directors, Representative Director, Chairman of the Board
Atsushi Maruo	Member of the Board of Directors, Vice Chairman of the Board
Sohta Yamaguchi	President, Member of the Board of Directors, Representative Director
Hiroyasu Nishioka	Managing Member of the Board of Directors, International Business Division Director, In Charge of Production Division
Yutaka Kaihori	Member of the Board of Directors, Executive Corporate Officer, Pharma Business Initiative
Maiko Mori	Member of the Board of Directors, Executive Corporate Officer Quality & Safety Assurance Division Director
Kunihiro Gunji	Audit & Supervisory Board Member
Kazuhiro Chiku	Audit & Supervisory Board Member

Corporate Officers

Kiyohiko Tamura	Executive Corporate Officer Administrative Division Director
Masaya Takanashi	Corporate Officer Development Division Director
Toshitaka Nakajima	Corporate Officer Production Division Director
Junko Komatsu	Corporate Officer Business Development Division Director
Tomohito Nagao	Corporate Officer Promotion Compliance Unit Director
Shuzo Watanabe	Corporate Officer Innovative Drug Discovery Division Director
Atsushi Ito	Corporate Officer Sales Division Director, Pharma Business Initiative
Hideaki Kobayashi	Corporate Officer Corporate Strategy Division Director

ASKA Animal Health Co., Ltd.

Board Members

Fumiyoshi Yamaguchi	President, Member of the Board of Directors, Representative Director In Charge of Development, Regulatory Affairs
Minehiro Okegawa	Senior Managing Member of the Board of Directors In Charge of Administration, Sales Support
Kiyohiko Tamura	Member of the Board of Directors
Kazuhiro Chiku	Audit & Supervisory Board Member

ASKA Pharma Medical Co., Ltd.

Board Members

Hidegori Hori	President, Member of the Board of Directors, Representative Director
Kiyohiko Tamura	Member of the Board of Directors
Kazumasa Watanabe	Member of the Board of Directors
Kunihiro Gunji	Audit & Supervisory Board Member

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp